Table 2. Uni-and multivariate analyses of CSR, obstructive sleep apnea and potential confounders.
| Variables | Primary end-point | Secondary end-point | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| CSR/OSA | 2.70 (1.01–7.22) | 0.047 | 4.73 (1.10–20.28) | 0.037 | 1.96 (1.06–3.63) | 0.032 | 2.15 (1.00–4.65) | 0.051 | |||
| Age | 1.04 (0.99–1.08) | 0.090 | 1.03 (0.98–1.09) | 0.263 | 1.01 (0.98–1.03) | 0.665 | 0.99 (0.96–1.02) | 0.519 | |||
| Body weight | 1.00 (0.98–1.03) | 0.911 | 1.02 (0.99–1.06) | 0.175 | 1.00 (0.97–1.01) | 0.901 | 1.00 (0.99–1.02) | 0.766 | |||
| LVEF | 0.96 (0.91–1.01) | 0.140 | 0.97 (0.92–1.02) | 0.235 | 0.99 (0.95–1.03) | 0.466 | 0.99 (0.95–1.03) | 0.572 | |||
| NYHA ≥ III | 1.92 (0.45–8.23) | 0.382 | 1.03 (0.14–7.68) | 0.974 | 1.11 (0.34–3.58) | 0.866 | 1.30 (0.32–5.29) | 0.716 | |||
| ACE/ATII-inhibitor | 0.76 (0.26–2.21) | 0.608 | 0.22 (0.04–1.14) | 0.071 | 1.33 (0.53–3.36) | 0.549 | 0.76 (0.25–2.34) | 0.631 | |||
| β-blockers | 0.36 (0.15–0.87) | 0.023 | 0.39 (0.13–1.15) | 0.088 | 0.49 (0.24–1.02) | 0.057 | 0.55 (0.24–1.27) | 0.163 | |||
| AHI | 1.02 (1.00–1.04) | 0.137 | 1.00 (0.98–1.02) | 0.896 | 1.01 (0.99–1.03) | 0.284 | 1.00 (0.98–1.02) | 0.815 | |||
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association class; CSR, Cheyne-Stokes respiration; OSA, obstructive sleep apnea; ACE, angiotensin-converting enzyme inhibitor; ATII-inhibitor, angiotensin II receptor antagonist; AHI, apnea-hypopnea index.